Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01549834 | Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | PHASE2 | COMPLETED | 434 | — | — | Mar 1, 2012 | Oct 1, 2013 | Oct 31, 2014 | 43 | United States, Canada +5 |
| NCT00948909 | Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 274 | — | — | Oct 1, 2009 | Nov 1, 2010 | Jan 31, 2013 | 29 | United States, Bulgaria +4 |
An assessment tool which focuses on cognitive function and memory
| Arm | Type | Description |
|---|---|---|
| ABT-126 Low Dose | EXPERIMENTAL | low dose |
| ABT-126 High Dose | EXPERIMENTAL | high dose |
| sugar pill | PLACEBO_COMPARATOR | Placebo |
| A. Sugar Pill | PLACEBO_COMPARATOR | - |
| B. ABT-126 | EXPERIMENTAL | - |
| C. ABT-126 | EXPERIMENTAL | - |
| D. donepezil | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-126 | DRUG | Low Dose |
| placebo | DRUG | Placebo |
| donepezil | DRUG | Active comparator intervention |
Inclusion Criteria: * The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject. * The sub...